Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sucampo/Takeda drug Amitiza wins 1st FDA nod in OIC non-cancer pain

This article was originally published in Scrip

Executive Summary

Sucampo Pharmaceuticals and its partner Takeda won the US FDA's blessing on 23 April to market Amitiza (lubiprostone) 24mcg twice daily as the first and only oral medicine to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts